The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study
Open accessAbstract
Purpose: To assess the risk of secondary nonbreast cancers (SNBCs) in a recently treated population-based cohort of breast cancer patients focused on the association with treatment and prognostic implications. Patients and Methods: In 58,068 Dutch patients diagnosed with invasive breast cancer between 1989 and 2003, SNBC risk was quantified using standardized incidence ratios (SIRs), cumulative incidence, and Cox regression analysis, adjusted for competing risks. Results: After a median follow-up of 5.4 years, 2,578 SNBCs had occurred. Compared with the Dutch female population at large, in this cohort, the SIR of SNBCs was increased (SIR, 1.22; 95% CI, 1.17 to 1.27). The absolute excess risk was 13.6 (95% CI, 9.7 to 17.6) per 10,000 person-years. SIRs were elevated for cancers of the esophagus, stomach, colon, rectum, lung, uterus, ovary, kidney, and bladder cancers, and for soft tissue sarcomas (STS), melanoma, non-Hodgkin's lymphoma, and acute myeloid leukemia (AML). The 10-year cumulative incidence of SNBCs was 5.4% (95% CI, 5.1% to 5.7%). Among patients younger than 50 years, radiotherapy was associated with an increased lung cancer risk (hazard ratio [HR] = 2.31; 95% CI, 1.15 to 4.60) and chemotherapy with decreased risk for all SNBCs (HR = 0.78; 95% CI, 0.63 to 0.98) and for colon and lung cancer. Among patients age 50 years and older, radiotherapy was associated with raised STS risk (HR = 3.43; 95% CI, 1.46 to 8.04); chemotherapy with increased risks of melanoma, uterine cancer, and AML; and hormonal therapy with all SNBCs combined (HR = 1.10; 95% CI, 1.01 to 1.21) and uterine cancer (HR = 1.78; 95% CI, 1.40 to 2.27). An SNBC worsened survival (HR = 3.98; 95%CI 3.77 to 4.20). Conclusion: Breast cancer patients diagnosed in the 1990s experienced a small but significant excess risk of developing an SNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
The role of diabetes mellitus in the aetiology of renal cell cancer
Lindblad, P., Chow, W. H., Chan, J., Bergström, A., Wolk, A., Gridley, G., McLaughlin, J. K., Nyrén, O., & Adami, H. O. (1999) · Diabetologia · doi:10.1007/s001250051122 · Cited by 220
Cited by
de Gonzalez, A. B., Curtis, R. E., Kry, S. F., Gilbert, E., Lamart, S., Berg, C. D., Stovall, M., & Ron, E. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70061-4 · Cited by 481
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Long-term toxic effects of adjuvant chemotherapy in breast cancer
Azim, H. A., de Azambuja, E., Colozza, M., Bines, J., & Piccart, M. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq683 · Cited by 292
Elkabets, M., Gifford, A. M., Scheel, C., Nilsson, B., Reinhardt, F., Bray, M.-A., Carpenter, A. E., Jirström, K., Magnusson, K., Ebert, B. L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43757 · Cited by 201
“As an example, some breast cancer patients develop contralateral breast cancer, which is a predictor of poor outcome (3, 4), and patients with synchronous bilateral breast cancer tend to have a significantly worse overall survival than those patients with metachronous or unilateral cancers (5).”
Metadata
- Authors
- Schaapveld, M., Visser, O., Louwman, M. J., de Vries, E. G. E., Willemse, P. H. B., Otter, R., van der Graaf, W. T. A., Coebergh, J.-W. W., & van Leeuwen, F. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-03-10
- Volume
- 26
- Issue
- 8
- Pages
- 1239-1246
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2098496930
- Cited by
- 211
- References
- 2
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.